136 related articles for article (PubMed ID: 6196180)
1. Dihydrotestosterone concentration of beagle prostatic tissue: effect of age and hyperplasia.
Ewing LL; Berry SJ; Higginbottom EG
Endocrinology; 1983 Dec; 113(6):2004-9. PubMed ID: 6196180
[TBL] [Abstract][Full Text] [Related]
2. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
Isaacs JT; Coffey DS
Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
[TBL] [Abstract][Full Text] [Related]
3. Subnormal tissue 3 alpha-androstanediol and androsterone in prostatic hyperplasia.
Meikle AW; Stringham JD; Olsen DC
J Clin Endocrinol Metab; 1978 Oct; 47(4):909-13. PubMed ID: 95628
[TBL] [Abstract][Full Text] [Related]
4. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
5. Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate.
Ghanadian R; Puah CM
J Endocrinol; 1981 Feb; 88(2):255-62. PubMed ID: 6162906
[TBL] [Abstract][Full Text] [Related]
6. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia.
DeKlerk DP; Coffey DS; Ewing LL; McDermott IR; Reiner WG; Robinson CH; Scott WW; Strandberg JD; Talalay P; Walsh PC; Wheaton LG; Zirkin BR
J Clin Invest; 1979 Sep; 64(3):842-9. PubMed ID: 89121
[TBL] [Abstract][Full Text] [Related]
7. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.
Trachtenberg J; Hicks LL; Walsh PC
J Clin Invest; 1980 May; 65(5):1051-9. PubMed ID: 6154062
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog.
Gloyna RE; Siiteri PK; Wilson JD
J Clin Invest; 1970 Sep; 49(9):1746-53. PubMed ID: 4194769
[TBL] [Abstract][Full Text] [Related]
9. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate.
Geller J; Albert J; Lopez D; Geller S; Niwayama G
J Clin Endocrinol Metab; 1976 Sep; 43(3):686-8. PubMed ID: 60347
[TBL] [Abstract][Full Text] [Related]
10. Decreased urinary 5 alpha-androstane-3 alpha,17 beta-diol glucuronide excretion in patients with benign prostatic hyperplasia.
Wright F; Poizat R; Bongini M; Bozzolan F; Doukani A; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1985 Feb; 60(2):294-8. PubMed ID: 2578133
[TBL] [Abstract][Full Text] [Related]
11. Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog.
Moore RJ; Gazak JM; Quebbeman JF; Wilson JD
J Clin Invest; 1979 Oct; 64(4):1003-10. PubMed ID: 90055
[TBL] [Abstract][Full Text] [Related]
12. Studies on the mechanism of 3 alpha-androstanediol-induced growth of the dog prostate.
Jacobi GH; Moore RJ; Wilson JD
Endocrinology; 1978 Jun; 102(6):1748-58. PubMed ID: 744048
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone accumulation in genital skin fibroblasts derived from elderly men with prostatic hyperplasia.
Morimoto I; Eto S; Inoue S; Izumi M; Hara T; Saito Y; Nagataki S
J Clin Endocrinol Metab; 1992 Aug; 75(2):632-5. PubMed ID: 1379259
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and histological studies on prostates in castrated dogs after treatment with androstanediol, oestradiol and cyproterone acetate.
Tunn U; Senge T; Schenck B; Neumann F
Acta Endocrinol (Copenh); 1979 Jun; 91(2):373-84. PubMed ID: 88858
[TBL] [Abstract][Full Text] [Related]
15. Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia.
Morimoto I; Edmiston A; Horton R
J Clin Invest; 1980 Sep; 66(3):612-5. PubMed ID: 6156957
[TBL] [Abstract][Full Text] [Related]
16. Androgens and estrogens in the plasma and prostatic tissue of normal dogs and dogs with benign prostatic hypertrophy.
Lloyd JW; Thomas JA; Mawhinney MG
Invest Urol; 1975 Nov; 13(3):220-22. PubMed ID: 53217
[TBL] [Abstract][Full Text] [Related]
17. Benign prostatic hyperplasia: etiological considerations.
Walsh PC
Prog Clin Biol Res; 1976; 6():1-8. PubMed ID: 66685
[TBL] [Abstract][Full Text] [Related]
18. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
Lamb JC; English H; Levandoski PL; Rhodes GR; Johnson RK; Isaacs JT
Endocrinology; 1992 Feb; 130(2):685-94. PubMed ID: 1733716
[TBL] [Abstract][Full Text] [Related]
19. DNA synthesis in the canine prostate: effects of androgen and estrogen treatment.
Barrack ER; Berry SJ
Prostate; 1987; 10(1):45-56. PubMed ID: 2434936
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous determination of testosterone, dihydrotestosterone and 5 alpha-androstan-3 alpha,-17 beta-diol by isotopic dilution mass spectrometry in plasma and prostatic tissue of patients affected by benign prostatic hyperplasia. Effects of 3-month treatment with a GnRH analog.
Salerno R; Moneti G; Forti G; Magini A; Natali A; Saltutti C; Di Cello V; Costantini A; Serio M
J Androl; 1988; 9(4):234-40. PubMed ID: 2460425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
